Experimental vaccine 1

Discontinued / Inactive

Developer: Sinovac Research and Development Co., Ltd.  |  Target Disease: COVID-19

Program Status: Inactive / Discontinued

Reason: Registry status: SUSPENDED

Stage at discontinuation: approved

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View COVID-19 Vaccine Guide →

Development discontinued.

Development Phase Discontinued / Inactive Primary Status
Platform Technology Inactivated Biologic Architecture
Target Indication COVID-19 Pathogen / Antigen
Last Verified 2026-10-30 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Not Filed / Pre-submission
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Progress and adoption outlook

Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Discontinued or withdrawn; tracked, not projected.

90% of the laddernot projected
  1. Preclinical
  2. Phase 1
  3. Phase 1/2
  4. Phase 2
  5. Phase 2/3
  6. Phase 3
  7. Submitted to a regulator
  8. Under regulatory review
  9. Approved / authorised
  10. Recommended for routine use

Stopped at Approved / authorised

Discontinued. No adoption window is projected for a stopped programme.

Scientific Profile & Documentation

Platform Architecture
Inactivated
Lead Developer
Sinovac Research and Development Co., Ltd.
Next Expected Milestone
Primary completion (most advanced trial): 2023-03-20 (registry estimate)
Analyst & Development Notes
Auto-grouped from 1 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation
ClinicalTrials.gov NCT05165732 →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT05165732 Discontinued / Inactive

Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manu

Status: Active / Ongoing • Expected Readout: 2023-03-20

Milestone Overview

  • Stage Verification
    Discontinued / Inactive confirmed as of 2026-10-30.
  • Target Milestone
    Primary completion (most advanced trial): 2023-03-20 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.